BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 22324859)

  • 21. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
    J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer.
    Johnston SR; Smith IE; Doody D; Jacobs S; Robertshaw H; Dowsett M
    Cancer Res; 1994 Nov; 54(22):5875-81. PubMed ID: 7954417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate.
    Lønning PE; Geisler J; Johannessen DC; Ekse D
    J Steroid Biochem Mol Biol; 1997 Apr; 61(3-6):255-60. PubMed ID: 9365198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer.
    Holmes CE; Huang JC; Pace TR; Howard AB; Muss HB
    Clin Cancer Res; 2008 May; 14(10):3070-6. PubMed ID: 18483373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aromatase inhibitors for treatment of breast cancer: current concepts and new perspectives.
    Santen RJ
    Breast Cancer Res Treat; 1986; 7 Suppl():S23-35. PubMed ID: 3527304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.
    Donders G; Neven P; Moegele M; Lintermans A; Bellen G; Prasauskas V; Grob P; Ortmann O; Buchholz S
    Breast Cancer Res Treat; 2014 Jun; 145(2):371-9. PubMed ID: 24718774
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measurable Serum Estradiol and Estrone in Women 36-56 Years During Adjuvant Treatment With Aromatase Inhibitors for a Hormone Receptor-Positive Breast Cancer. Case Studies and Cross-sectional Study Using an Ultra-sensitive LC-MS/MS-Method.
    Van Houdt M; Han SN; Pauwels S; Billen J; Neven P
    Clin Breast Cancer; 2023 Jan; 23(1):84-90. PubMed ID: 36376236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients.
    Bertelsen BE; Viste K; Helland T; Hagland M; Søiland H; Geisler J; Lende TH; Lønning PE; Sagen JV; Mellgren G; Almås B
    J Clin Endocrinol Metab; 2022 Apr; 107(5):1368-1374. PubMed ID: 34958096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.
    Geisler J; Helle H; Ekse D; Duong NK; Evans DB; Nordbø Y; Aas T; Lønning PE
    Clin Cancer Res; 2008 Oct; 14(19):6330-5. PubMed ID: 18829517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis.
    Punglia RS; Kuntz KM; Winer EP; Weeks JC; Burstein HJ
    Cancer; 2006 Jun; 106(12):2576-82. PubMed ID: 16703595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The estrogen suppression after sequential treatment with formestane in advanced breast cancer patients.
    Zilembo N; Bajetta E; Bichisao E; Martinetti A; La Torre I; Bidoli P; Longarini R; Portale T; Seregni E; Bombardieri E
    Biomed Pharmacother; 2004 May; 58(4):255-9. PubMed ID: 15183852
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aromatase inhibitors and the endometrium.
    Cohen I
    Maturitas; 2008 Apr; 59(4):285-92. PubMed ID: 18448280
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer.
    Baumgart J; Nilsson K; Evers AS; Kallak TK; Poromaa IS
    Menopause; 2013 Feb; 20(2):162-8. PubMed ID: 22990756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of tamoxifen and aromatase inhibitors on breast tissue enhancement in dynamic contrast-enhanced breast MR imaging: a longitudinal intraindividual cohort study.
    Schrading S; Schild H; Kühr M; Kuhl C
    Radiology; 2014 Apr; 271(1):45-55. PubMed ID: 24475835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
    Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
    Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in serum estradiol levels with Estring in postmenopausal women with breast cancer treated with aromatase inhibitors.
    Streff A; Chu-Pilli M; Stopeck A; Chalasani P
    Support Care Cancer; 2021 Jan; 29(1):187-191. PubMed ID: 32328775
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.